Anti-inflammatory Effect of Alloferon on Ovalbumin-induced Asthma.
- Author:
Jane JEON
1
;
Yejin KIM
;
Hyemin KIM
;
Jae Seung KANG
;
Wang Jae LEE
Author Information
- Publication Type:Original Article
- Keywords: Alloferon; Asthma; Interleukin-17
- MeSH: Animals; Asthma*; Bronchioles; Bronchoalveolar Lavage Fluid; Down-Regulation; Eosinophils; Immunoglobulin E; Immunoglobulin G; Immunoglobulins; Interleukin-17; Interleukin-5; Lung Diseases; Macrophages; Mice; Neutrophils; Ovalbumin; Pneumonia; Prednisolone
- From:Immune Network 2015;15(6):304-312
- CountryRepublic of Korea
- Language:English
- Abstract: Asthma is a well-known inflammatory lung disease; however, the specific underlying mechanism is largely unknown. We previously demonstrated that alloferon effectively downregulates pulmonary inflammation. In this study, we examined whether alloferon has a therapeutic effect on asthma. Alloferon remarkably decreased the number of eosinophils, macrophages, and neutrophils in the bronchoalveolar lavage fluid (BALF) from ovalbumin (OVA)-induced asthma mice. It was synergistically decreased with 2.5 mg/kg prednisolone (PDA). Inflammatory cell infiltration around the bronchioles and in the alveolus of OVA-induced asthma mice was effectively prevented by alloferon alone and combined treatment with alloferon and PDS. The production of IL-5 and IL-17 was decreased by alloferon alone and combined treatment with alloferon and PDS. There was no change the level of total immunoglobulin (Ig) following alloferon administration; however, total Ig was decreased by PDS. IgG2a levels were not changed by either alloferon alone or alloferon in combination with PDS. However, the levels of OVA-specific IgG1 and IgE were decreased by alloferon and PDS. In conclusion, our results suggest that a combination of alloferon and prednisolone is effective for the treatment of asthma, as it prevents inflammatory cell infiltration via the down-regulation of IL-5 and IL-17 production and decreases IgG1 and IgE production via the suppression of T helper type 2 immune response.
